Search the RE article base
Contact Information
Twitter
My TweetsUseful Web Sites
Category Archives: Bayh-Dole
Bayh-Dole, Federal Agency Conflict of Interest, and the Covid Vaccines
Here is a recent video clip of an interview with Robert F. Kennedy, Jr. He asserts that it was known that HCQ and Ivermectin were effective in treating corona viruses by 2004. Robert F. Kennedy Jr. claims that "We knew … Continue reading
Faculty Strategies for Getting Their IP Back, 2
Here are some strategies for getting IP back that don’t work or avoid IP ownership. (1) Don’t disclose an invention to the university, and file for a patent on your own. Your application will be published in a year or … Continue reading
AUTM arguments for not complying with Bayh-Dole
Just a quick note here on AUTM arguments are for not complying with Bayh-Dole. Just off a meeting that paid attention to AUTM’s position. I’ll summarize the main arguments here. Access in the form of commercial products is more important … Continue reading
Posted in Bayh-Dole, Policy
Tagged B.S., Bayh-Dole, reasonable use
Comments Off on AUTM arguments for not complying with Bayh-Dole
Xtandi, Bayh-Dole, and how Pfizer might stop worrying and love the march in
The American Prospect has an interesting piece (“A Big Miss on Drug Prices”) on the NIH yet again defying the Bayh-Dole Act and refusing to launch an investigation into whether UCLA and Pfizer have met Bayh-Dole’s standard (35 USC 201(f)) … Continue reading
Posted in Bayh-Dole
Tagged administration agreement, Bayh-Dole, march-in, patent rights clause, Xtandi
Comments Off on Xtandi, Bayh-Dole, and how Pfizer might stop worrying and love the march in
Inventors would own more, were it not for noncompliant Bayh-Dole practice
I saw this tweet this morning: I agree Inventors should own more, but institutions were/are the heart of Bayh-Dole that (arguably) enables IP-driven startups… this is bc many/most PI inventions would go into a black hole without tech transfer officer … Continue reading
Why not let’s try, Frank?
Frank Cullen, writing at the “Council for Innovation Promotion” has posted a hand-wringing response to a letter from members of Congress to the Secretary of Health and Human Services requesting that the government use Bayh-Dole’s march-in provisions to address price … Continue reading
March-in rights, Xtandi, and Bayh-Dole’s patent rights clause
Senator Bernie Sanders just tweeted about Xtandi, asking patients taking Xtandi to share their stories. The prostate cancer drug Xtandi was invented by taxpayer-funded scientists at UCLA, but now costs Americans nearly $190,000 — or up to six times the … Continue reading
Posted in Bayh-Dole, high priced drugs
Tagged Bayh-Dole, competition, march-in, reasonable terms, Xtandi
Comments Off on March-in rights, Xtandi, and Bayh-Dole’s patent rights clause
NIAID Breezily Repudiates Supreme Court Ruling
Perhaps you wanted a short version. NIAID puts this in guidance to inventors regarding inventions made in NIH-funded work: Under the Bayh-Dole Act, your institution as the grant recipient owns rights to the NIH-funded invention and has the right and … Continue reading
NIAID botches Bayh-Dole
This will be a bit of a long ride. Buckle up. In 2011, the US Supreme Court ruled in Stanford v Roche that the Bayh-Dole Act does not vest title to inventions made in federally supported work with the nonprofit … Continue reading